Skip to content

The efficacy of regional citrate anticoagulation in maintenance hemodialysis with high risk of bleeding: an open label multicenter randomized controlled trials

The efficacy of regional citrate anticoagulation in maintenance hemodialysis with high risk of bleeding: an open label multicenter randomized controlled trials

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027425
Enrollment
Unknown
Registered
2019-11-12
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis

Interventions

treatment group:regional citrate anticoagulatio
Control group:heparin-free hemodialysis

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who receive maintenance hemodialysis because of renal failure. 2. Aged between 18 to 70 years old; 3. There is active bleeding or high risk of bleeding (such as gastrointestinal bleeding, cerebral bleeding, bleeding at the surgical site, etc.), and heparin or low molecular weight heparin should not be used for anticoagulation. 4. The hemoglobin level between 70 to120g/L; 5. The platelet levels between 100 to 350 x 10^9/L; 6. The blood calcium level 1.8~2.5mmol/L; 7. The Vascular access type is arteriovenous autologous fistula or deep venous indentation catheter; 8. Stable hemodynamics; 9. Clear consciousness; 10. Normal cognition and high compliance, and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. A history of sodium citrate allergies; 2. With liver cirrhosis or significant impairment of liver function; 3. Extensive muscle tissue injury or hypoperfusion of muscle tissue; 4. Oxygen inhalation by mask or oxygenation index <300mmHg is required; 5. Hemophilia or other coagulopathies; 6. With severe systemic infections; 7. Patients who can not cooperate because of mental illness ; 8. Any other conditions that the researchers think the subject can't attend the study.

Design outcomes

Primary

MeasureTime frame
Fiter and venous trap clotting;

Secondary

MeasureTime frame
Blood routine;Blood chemistry;blood gas analysis;PT;APTT;metabolic alkalosis;

Countries

China

Contacts

Public ContactZhang Ling

Nephrology Department, West China Hospital, Sichuan University

zhanglinglzy@163.com+86 18980601985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026